GBG
Government
Bioscience
Grants

Updated Monthly

November 10, 2026

Prepared for:

BIOUTAH

THE ESSENTIAL GUIDE TO

Non-Dilutive Government Funding



Published by:

G2G Consulting

Questions?

Liz Powell, Esq., MPH
lpowell@G2Gconsulting.com
www.G2Gconsulting.com
@G2Gconsulting

GBG Report

Updated Monthly

November 10, 2026

https://www.g2gconsulting.com/gbg-reporting-service/

TABLE OF CONTENTS

New Opportunities

Aging 2
Alcohol Use Disorder 3
Antimicrobial Resistance 3
Artificial Intelligence & Machine Learning 3
Bioengineering 5
Biomedical Research 5
Biotechnology and Biomanufacturing 6
Cancer 6
Clinical Trials 7
Cognitive and Brain Health 8
Communication Disorders 8
Endocrine & Metabolic Disease 9
Energy Science 9
Genomics 10
HIV/AIDS 10
Immunology & Infectious Disease 10
Medical Countermeasures 12
Medical Manufacturing 12
Musculoskeletal Health 12
Parkinson's Disease 13
Patient-Centered Research 13
Pediatric Health 13
Regulatory Science 14
Reproductive Health 14
Small Business Development 14
Therapeutics 15
Urology 15
Women's Health 15

Recurring Opportunities

Advanced Research Projects Agency for Health 17
Air Force 18
Army 19
BARDA 21
DARPA 21
Defense Threat Reduction Agency 22
Department of Energy 22
National Science Foundation 23
Navy 24
Office of the Undersecretary of Defense 24
Patient-Centered Outcomes Research Institute 24

GBG Acronyms 26

GBG Report

Updated Monthly

November 10, 2026

https://www.g2gconsulting.com/gbg-reporting-service/

November 19, 2026 – Join us for G2G's Monthly Non-Dilutive Funding: GBG Reporting Service Webinar at 12-12:30pm EST (FREE to all) and 12:30-1:00pm (premium service private consultation for G2G and GBG clients). If you're an affiliate of Biocom, BioUtah, Bio Nebraska, Focused Ultrasound Foundation, iBIO, Indiana Life Sciences Association, Georgia Life Sciences, IowaBio, MichBio, NCBiotech, Ohio Life Sciences, South Dakota Biotech, VaBio, or BioWV – your membership gets you access to the private consultation meeting.

December 10, 2026 – Learn from G2G's Experts on securing government funding. G2G Founder Liz Powell, Esq., MPH, will moderate a fireside chat with G2G VP Becky Watts, former Appropriations Director for then U.S. Senator Mike DeWine, and Director Chris Cooper, former Chief Appropriations Counsel and Chief of Staff for U.S. Rep. Dave Joyce. Dial in to hear how the money flows and how to access it! Register here!

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AGING (3)		
1.	Palliative Care Research Across the Lifespan: Leveraging the Palliative Care Consortium (R01 Clinical Trial Optional) (NIH/NIA) PAR-27-090	This NOFO invites applications proposing research on palliative care across the lifespan for persons with serious illnesses and/or their care partners, including projects focused on palliative care access, use, and quality. https://www.grants.gov/search-results-detail/360675	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 10/5/29
2.	Forecast: Coordinating Center for the Claude D. Pepper Older Americans Independence Centers (OAICs) (NIH/NIA) RFA-AG-28-002	The CC serves as a facilitator for OAIC site interactions and as a conduit for translating OAIC objectives and findings to both scientific and general audiences. The proposed CC must demonstrate an ability to work cooperatively with all OAIC sites and possess sufficient scientific expertise in geriatrics and related areas to serve the national coordination functions of the OAIC program. https://www.grants.gov/search-results-detail/364065	TBD	Estimated post date: 3/25/27 Estimated due date: 5/25/27
3.	2027 NIA Start-Up Challenge and Accelerator (NIH/NIA)	This Challenge is interested in ideas for innovative tools, technologies, and interventions that prevent, diagnose, treat, monitor, or slow progression of aging-related diseases and conditions, including Alzheimer's disease (AD) and AD-related dementias, as well as solutions that promote healthy aging, support aging in place of choice, improve care delivery, or reduce caregiving burden. https://www.nih.gov/challenges/2027-nia-start-challenge-accelerator	Accelerator program and prizes totaling $994,000	Submission window: 12/1/26-1/15/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ALCOHOL USE DISORDER (1)		
4.	Specialized Alcohol Research Centers (P50 Clinical trial Optional) (NIH/NIAAA) RFA-AA-28-001	The focus of the NIAAA Centers program should be on generating a critical mass of researchers in a given understudied and/or innovative topic area relevant to the NIAAA mission with an emphasis on interdisciplinary coordination and cooperation among independent researchers and development and mentorship of young investigators. https://www.grants.gov/search-results-detail/361216	Up to $1.15 million per year, for up to 5 years	Proposal: 1/27/27
		ANTIMICROBIAL RESISTANCE (1)		
5.	CARB-X 2026 (CARB-X)	The second CARB-X 2026 funding round includes four distinct product themes: Direct-acting therapeutics for infections caused by gram-negative bacteria; Novel chemistry scaffolds with activity against validated bacterial targets; Non-vaccine approaches for preventing neonatal sepsis; and Diagnostics for neonatal sepsis. https://carb-x.org/apply/funding-themes/	Up to $1 million, for up to 2 years	Submission window: 11/10-23/26
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING (6)		
6.	AITC Annual National Research Award Competition (NIH/NIA/AITC) AITC-ARA-27-001	The competition funds cutting-edge AI and technology approaches to advance aging and AD/ADRD research. Projects may develop a new AI-enabled tool or technology; adapt, integrate, or strengthen an existing technology for a new aging or AD/ADRD application; or evaluate a technology's feasibility, usability, effectiveness, safety, or implementation with older adults, caregivers, clinicians, or health systems. https://aitcc.ai/rfa/aitc-ara-27-001	Up to $300,000, for up to 2 years	Letter of intent: 11/16/26 Proposal: 1/22/27
7.	Advance Whole-Person Data Integration and Reimagine Data Science Computations and Analytics to Address Chronic Disease Disparity Grand Challenge (NIH/NIMHD)	This Grand Challenge seeks to prepare big data for AI health disparities research that addresses chronic disease(s). It is imperative that the data be tested for representation of the populations and other fit-for-purpose features it will address. The deliverable must be accessible to other researchers. https://www.nimhd.nih.gov/resources/schare/grand-challenges/advance-whole-person-data-integration-and-analytics	Total prizes of $1 million	Proposal: 1/22/27
8.	Digital Twins and/or Synthetic Data Population Modeling for Whole-Person Health to Mitigate Chronic Disease Disparities Grand Challenge (NIH/NIMHD)	This Grand Challenge seeks innovative digital twin and synthetic population modeling approaches that advance whole-person/exposome chronic disease research and/or health care by integrating real-world biomedical, behavioral, mental health, environmental, healthcare, and community data into AI-ready computational models. https://www.nimhd.nih.gov/resources/schare/grand-challenges/digital-twins-and-synthetic-data-population-modeling	Total prizes of $1 million	Proposal: 4/19/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARTIFICIAL INTELLIGENCE & MACHINE LEARNING		
9.	Smart Devices and Sensing Technologies to Mitigate Chronic Disease Disparities Grand Challenge (NIH/NIMHD)	This Grand Challenge seeks to accelerate the development of innovative, interoperable, and scalable sensing technologies that improve early detection, continuous monitoring, prevention, and management of chronic diseases among populations experiencing the greatest burden of disease. Participants will design, prototype, and validate smart devices, wearable sensors, mobile technologies, digital biomarkers, software applications, or integrated sensing ecosystems that leverage artificial intelligence, cloud computing, and whole-person data to improve chronic disease prevention and intervention strategies. https://www.nimhd.nih.gov/resources/schare/grand-challenges/smart-devices-and-sensing-technologies	Total prizes of $1 million	Proposal: 2/15/27
10.	The Semantic Precision for AI Retrieval of Knowledge (SPARK) dbGaP Challenge (NIH/NLM)	The SPARK dbGaP Challenge aims to advance the biomedical data and tools of the National Institutes of Health (NIH) and National Library of Medicine (NLM), making these resources high-quality, trusted, and widely used for public benefit. Specifically, this challenge is to build a modern, AI-powered search engine to identify relevant biomedical research studies that explore genomic and phenotypic associations stored within the NLM Database of Genotypes and Phenotypes (dbGaP). Right now, public dbGaP study metadata and variable descriptions are heterogeneous across studies making study discovery haphazard and cross-study comparison difficult. https://www.nih.gov/challenges/semantic-precision-ai-retrieval-knowledge-spark-dbgap-challenge	Total prizes of $250,000	Submission window: 1/18-31/27
11.	The Semantic Precision for AI Retrieval of Knowledge (SPARK) PubMed/PMC Challenge (NIH/NLM)	The SPARK Challenge aims to advance the biomedical data and tools of the National Institutes of Health (NIH) and National Library of Medicine (NLM), making these resources high-quality, trusted, and widely used for public benefit. NIH/NLM encourages broad use of the resources it generates and treats data shared through its mechanisms as a common foundation for open discovery, freely available for everyone to build upon. Ultimately, this challenge aims to catalyze the development of AI-powered systems capable of generating synthesized, citation-backed responses that support complex literature exploration and help biomedical researchers identify and take appropriate next steps, substantially reducing the time and cognitive burden associated with navigating and interpreting the scientific literature. https://www.nih.gov/challenges/semantic-precision-ai-retrieval-knowledge-spark-pubmedpmc-challenge	Total prizes of $250,000	Submission window: 1/18-31/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOENGINEERING (1)		
12.	NSF X-Labs Initiative - From Sequence to Function (NSF) NSF-Topic4-FY26-XLabsSequence-to-Function	An NSF X-Labs Mission in this Topic must be transformative, accelerating breakthroughs in our understanding of the relationship between sequence and function, and catalyzing capabilities to engineer proteins or entire genomes with exceptional new capabilities. Successful teams will develop platform technologies, demonstrate measurable impact on the U.S. biotechnology landscape, and position their technologies for widespread use by overcoming technical barriers that limit implementation and investment. https://sam.gov/workspace/contract/opp/4da70f039bbc4e2fbddce36bc55ab394/view	Dependent upon proposal and award mechanism	Proposal: 2/8/27
		BIOMEDICAL RESEARCH (4)		
13.	NIH Research Program Projects (Parent P01 Clinical Trial Optional) (NIH) PA-27-061	Through this NOFO, NIH invites applications proposing multidisciplinary, coordinated research programs that represent the investigators' specific interests and competencies and that fall within the mission of the participating NIH Institutes Centers, and Offices (ICOs). The goal of the Program Project is to support an integrated, collaborative research program composed of interrelated projects that address a well-defined central research focus or objective. https://www.grants.gov/search-results-detail/361279	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 5/25/29
14.	Collaborative Program Grant for Interdisciplinary Teams (RM1 Clinical Trial Optional) (NIH) PAR-27-003	The Team Science Grant is designed to support interdisciplinary research that offers significant advantages over supporting individual research grants or Program Project/Center grants, which often have separate aims or components. Interdisciplinary research teams must have a highly integrated approach to tackle a single, focused scientific problem and achieve anticipated outcomes. https://www.grants.gov/search-results-detail/361322	Up to $1.5 million per year, for up to 5 years	Multiple deadlines; NOFO open through 9/26/29
15.	NextTech: Translational Development of Next-Generation Diagnostic and Therapeutic Devices (R18 Clinical Trial Not Allowed) (NIH) RFA-EB-28-004	This NOFO encourages applications from investigators to advance the development and translation of next-generation technologies to prevent, monitor, diagnose, and treat disorders within the missions of the BRAIN and HEAL Initiatives. Awarded activities will facilitate the translation of new devices up to the stage of readiness for first in human (FIH) clinical trials by overcoming key challenges identified during preliminary proof-of-concept studies. The scope of the program includes technology development and optimization, and studies to prepare for approvals for human use. https://www.grants.gov/search-results-detail/361380	Dependent upon proposal, for up to 3 years	Multiple deadlines; NOFO open through 2/1/2030

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BIOMEDICAL RESEARCH		
16.	QuSAFE: Quantum-Enabled Approaches for Predictive Preclinical NAMs for Toxicity and Safety (NIH/NASA)	This Challenge aims to identify and develop proof-of-concept and prototype sensing systems that demonstrate how quantum-enabled approaches alone or in hybrid quantum-classical and other advanced sensing and detection approaches and configurations can improve detection and measurement in in vitro NAMs for toxicity, safety and other preclinical assessments. The goal is to enable new types of data and biological signals that cannot be measured today, thereby improving the predictive capability of preclinical models to generate robust, human-relevant data for drug development and safety evaluation. https://www.nih.gov/challenges/qusafe	Total prizes of $7.1 million	Proposal: 12/31/26
		BIOTECHNOLOGY AND BIOMANUFACTURING (1)		
17.	Future Program: Laguna (DoD/DARPA) DARPA-SN-27-15	The DARPA Laguna program aims to restore U.S. materials dominance by developing revolutionary direct-to-formulation technologies. By converging innovative bio-inspired enzymatic synthesis, advanced polymer chemistry, and multi-property modeling, Laguna transforms simple, domestically abundant raw materials — such as agricultural sugars, ethylene, and simple aromatics — directly into next-generation specialty chemicals and formulated mixtures. https://sam.gov/opp/9fe8c170741e474390b14912d103fd99/view	TBD	TBD
		CANCER (3)		
18.	Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional) (NIH/NCI) PAR-28-014	This NOFO invites applications that investigate the etiology of sporadic non-hereditary early-onset cancers (EOCs: ages 18 to 49 years) and the underlying biological mechanisms that play a role in these cancers to inform prevention and control strategies. The proposed research is expected to advance the understanding of the unexplained rise of cancers in young adults. https://www.grants.gov/search-results-detail/361438	Up to $500,000 per year, for up to 5 years	Multiple deadlines; NOFO open through 10/11/29
19.	Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required) (NIH/NCI) PAR-28-022	The program will fund P50 SPORE grants to support state-of-the-art investigator-initiated translational research that will contribute to improved prevention, early detection, diagnosis, and treatment of an organ-specific cancer or a highly related group of cancers. The research supported through this program must be translational and be based on human biology research using cellular, molecular, structural, biochemical, and/or genetic experimental approaches. https://www.grants.gov/search-results-detail/360541	Up to $1.4 million per year, for up to 5 years	Multiple deadlines; NOFO open through 9/25/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CANCER		
20.	Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical Trial Not Allowed) (NIH/NCI) PAR-28-042	This NOFO supports the analytical and clinical validation of molecular, cellular, and imaging biomarkers and assays for cancer detection, diagnosis, prognosis, monitoring, prediction of response or resistance to treatment, cancer prevention and control, as well as pharmacodynamic markers and markers of toxicity. https://www.grants.gov/search-results-detail/360946	Up to $275,000 for up to 2 years (UH2) Up to $250,000 per year, for up to 3 years (UH3)	Multiple deadlines; NOFO open through 10/16/29
		CLINICAL TRIALS (4)		
21.	Assessing the Feasibility of Incorporating Mechanisms in Multi-site Clinical Trials of Mind and Body Interventions on Whole Person Health Restoration (R33 Clinical Trial Required) (NIH/NCCIH) PAR-28-091	This NOFO solicits applications for multi-site feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) to reproduce and translate mechanisms of emotional well-being (EWB) into large-scale clinical trials that advance our understanding of whole person health. https://www.grants.gov/search-results-detail/359941	Dependent upon proposal, for up to 4 years	Multiple deadlines; NOFO open through 10/16/29
22.	Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional) (NIH/NIDA) PAR-28-093	This NOFO supports pilot and feasibility studies to inform the design and conduct of efficacy, effectiveness, and/or services research trials. Topics may include: 1) developing interventions to prevent substance use, misuse, or progression to substance use disorder; 2) prevention, treatment, or recovery services research, including research addressing comorbid pain and medical and mental health disorders; and 3) HIV eradication research, including implementation science, prevention, treatment and recovery in substance use settings/populations. https://www.grants.gov/search-results-detail/361204	Up to $450,000, for up to 3 years	Multiple deadlines; NOFO open through 6/16/29
23.	Immune Tolerance Network (UM1 Clinical Trial Required) (NIH/NIAID) RFA-AI-28-005	The primary objective of the Network is to develop tolerogenic therapies for immune-mediated disorders. The three main clinical areas of work are: 1) Allergic diseases and asthma; 2) Autoimmune diseases; and 3) Immune-mediated consequences of transplantation. The core functions of the ITN include designing, conducting, and sharing the results of clinical trials and performing integrated mechanistic studies. https://www.grants.gov/search-results-detail/362946	Up to $23 million per year, for 7 years	Proposal: 1/29/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		CLINICAL TRIALS		
24.	Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-28-012	This NOFO will establish a consortium of Translational Centers using MPS for Infectious Diseases (TCMID) that will have the following goals: Refine human cell-based MPS models of infectious diseases that are fit-for-purpose for advancing study of medical interventions; Establish specific endpoints in the MPS models, focused on regulatory validation requirements, that define human pathophysiological responses to infection as indicators of therapeutic efficacy; Establish 2-4 specific Contexts of Use (COU) for each Center, with the goal of submitting to the FDA a LOI targeting the Drug Development Tools (DDT) Qualification program or the Fit-for-Purpose Initiative. https://www.grants.gov/search-results-detail/362954	Dependent upon proposal, for up to 5 years	Proposal: 1/29/27
		COGNITIVE AND BRAIN HEALTH (1)		
25.	Genomic and Biologic Therapies for ADRD (U01 Clinical Trial Optional) (NIH/NINDS/NIA) RFA-NS-28-012	This NOFO supports the translation of genome editing and other biologic therapies for ADRD. The program spans the full translational pipeline, from therapeutic lead optimization and drug product development through IND-enabling studies and early clinical evaluation. Supported activities may include optimization of editing constructs and delivery systems; assessment of bioactivity, target engagement, durability, pharmacokinetics, and bioavailability; demonstration of in vivo efficacy; execution of safety pharmacology and toxicology studies; and development of scalable manufacturing processes, formulation strategies, and quality attributes aligned with regulatory expectations. https://www.grants.gov/search-results-detail/361287	Up to $1.3 million per year, for up to 5 years; up to $2.5 million per year if a Phase 1 clinical trial is included	Multiple deadlines; NOFO open through 10/10/28
		COMMUNICATION DISORDERS (2)		
26.	National Resource Network and Coordinating Center for the Study of Human Auditory and Vestibular Disorders (U24 Clinical Trial Not Allowed) (NIH/NIDCD) RFA-DC-28-001 RFA-DC-28-002	These NOFOs support laboratories and a coordinating center that constitute a collaborative network, the NIDCD National Human Ear Resource Network, to serve as a national technological resource for auditory and vestibular researchers to use human inner and middle ear tissues for a range of basic and clinical studies to advance knowledge and treatment of auditory and vestibular disorders. https://www.grants.gov/search-results-detail/361207 https://www.grants.gov/search-results-detail/361208	Up to $450,000 per year, for up to 5 years (Lab) Up to $200,000 per year, for up to 5 years (CC)	Multiple deadlines; NOFO open through 11/1/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ENDOCRINE & METABOLIC DISEASE (3)		
27.	Forecast: Leveraging NAMs to understand disease triggers, discover early biomarkers and develop new classes of therapeutic strategies for Type 1 Diabetes (U01 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-28-113	This NOFO will support research using human-relevant NAMs to advance understanding of the earliest events that initiate and drive T1D. Projects will use human cells and tissues and innovative experimental and computational approaches–including organoids, microphysiological systems, and other advanced human-relevant models–to investigate cellular and molecular mechanisms involved in T1D initiation and early disease progression. The research is expected to identify and validate early biomarkers and therapeutic targets and advance new strategies to prevent or interrupt disease progression before substantial pancreatic beta cell loss occurs. https://www.grants.gov/search-results-detail/364219	Total funding of $12 million	Estimated post date: 12/1/26 Estimated due date: 2/10/27
28.	The NIDDK Disorders of Gastrointestinal Interoception Consortium (DGIC) - Clinical Research Centers (U01 Clinical Trial Not Allowed) and Scientific Data Research Center (U24 Clinical Trial Not Allowed) (NIH/NIDDK) RFA-DK-28-213 (U01) RFA-DK-28-214 (U24	The overall objectives of this consortium are to: 1) identify the underlying mechanisms that link altered GI interception more directly to GI dysmotility and symptoms; 2) identify disease or response biomarkers that better assess pathophysiology or treatment efficacy; and 3) leverage state-of-the-art technologies to identify novel therapeutic targets that could be assessed in future clinical trials. https://www.grants.gov/search-results-detail/360625 (U01) https://www.grants.gov/search-results-detail/360623 (U24)	Up to $500,000 per year, for up to 5 years (U01) Up to $950,000, for up to 5 years (U24)	Proposal: 2/5/27
		ENERGY SCIENCE (1)		
29.	Opportunity to collaborate using a Cooperative Research and Development Agreement (CRADA) (DoE) 27_01	A CRADA Participant benefits from Sandia's programs and capabilities to potentially improve products/technologies for increased commercialization opportunities, furthers understanding of fundamental science in academia, and/or provides cutting-edge capabilities to help ensure our nation's security. NTESS and DOE benefit from collaborative research supporting DOE missions and program objectives. https://sam.gov/workspace/contract/opp/37637ecd810046de93b74db6a8d48b43/view	Dependent upon proposal and available funds	Proposal: 5/2/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		GENOMICS (1)		
30.	Forecast: Testing Centers for Evaluation of Somatic Cell Genome Editing Approaches for Translational Applications (U42 Clinical Trial Not Allowed) (NIH) PAR-28-084	Each center will provide resources and testing services to the growing community, developing new genome editing technologies and conducting preclinical testing based on these technologies for therapeutics for human diseases. The testing centers will work with NIH-funded investigators to assess the efficacy and safety of genome editing and delivery technologies, determine genome editing thresholds for specific diseases associated with minimal off-target effects, and ascertain feasibility parameters in model systems. https://www.grants.gov/search-results-detail/364066	Up to $900,000	Estimated post date: 11/25/27 Estimated due date: 1/25/28
		HIV/AIDS (1)		
31.	Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) (P30 Clinical Trial Not Allowed) (NIH/NIAID) PAR-28-090	This NOFO invites applications for the CFAR and D-CFAR programs to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide infrastructure, expertise, resources, and services not readily obtained through other funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research. https://www.grants.gov/search-results-detail/360869	Dependent upon proposal, for up to 5 years	Multiple deadlines; NOFO open through 5/25/29
		IMMUNOLOGY & INFECTIOUS DISEASE (8)		
32.	Pre-Clinical Models of Infectious Diseases (NIH/NIAID) 75N93027R00003	The current NIAID Preclinical Models of Infectious Diseases IDIQ contract program is one of DMID's preclinical services resources and supports the development and refinement of animal models and animal replacement models of infectious diseases, models that subsequently are used to evaluate candidate medical countermeasures against these diseases. In addition, these contracts facilitate regulatory submissions, patents, and other intellectual property applications by extramural investigators who request evaluation of their products. This program serves the DMID mission of supporting investigator-initiated research by providing critical data needed to apply for grant or other funding. Finally, these contracts enable product developers and sponsors to make key go/no-go decisions for candidate therapeutics, vaccines, and diagnostics. In addition to meeting the needs of extramural researchers, this program provides crucial data to our DHHS agency partners. These data will facilitate the advancement of promising candidate medical countermeasures against priority biodefense and emerging infectious agents to approval or licensure, and, in some cases, eventual deposit in the Strategic National Stockpile. https://sam.gov/workspace/contract/opp/48e64180d8534cc19ddbaf03306a366c/view	Presolicitation	Response: 12/7/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
33.	Systems Biology of Infection and Inflammation in Chronic Diseases (U19 Clinical Trial Not Allowed) (NIH) RFA-AI-28-014	The purpose of this NOFO is to support the advancement of systems-level understanding of the link between infectious pathogens and inflammatory pathways that result in predisposition, onset and progression of chronic diseases. The NOFO will stimulate integration of clinical and patient data, large-scale omics datasets, AI and computational modeling to prevent, treat, and mitigate the combined impact of chronic diseases, inflammation, and infections. https://www.grants.gov/search-results-detail/362952	Dependent upon proposal and Institute	Proposal: 1/18/27
34.	Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) (NIH/NIAID) RFA-AI-28-024	NIAID seeks to support basic research, discovery, and/or preclinical development of highly efficacious vaccines for malaria and potentially other mosquito-borne illness. The program will encourage novel approaches to vaccine design that capitalize on recent technological innovations including structure-based immunogen design, and/or combination vaccines to reduce parasite infection and/or reduce malaria disease burden. https://www.grants.gov/search-results-detail/361832	Up to $400,000 per year, for up to 3 years (R61) Up to $750,000 per year, for up to 2 years (R33) Up to $3 million per year, for up to 5 years (UM1)	Proposal: 2/11/27
35.	Hit-to-Lead Platform (HTLP) (GHIT Fund)	The Hit-to-Lead Platform (HTLP) leverages the medicinal chemistry expertise in Japan and facilitates access to relevant and diverse compounds to address the unmet needs of the following diseases: Malaria; Tuberculosis; Chagas Disease; Schistosomiasis; and Viral Infectious Diseases with Pandemic Potential. HTLP focuses on the aspect of the drug discovery and development process that advances hits, identified through compound library screening, into lead compounds that can then be optimized into drug candidates. https://www.ghitfund.org/applyforfunding/htlp/en	Dependent upon proposal and award mechanism	Letter of intent: 1/8/27 Proposal: 3/12/27
36.	Product Development Platform (GHIT Fund)	The GHIT Fund announces the RFP for the development of new medicines, vaccines, diagnostics for infectious diseases that are prevalent in the developing world. Proposed projects should address health needs in the developing world or fill a gap in global health technologies for infectious diseases. The proposed collaboration projects may focus on R&D activities in the development stages as illustrated in https://www.ghitfund.org/applyforfunding/opportunities, including: Lead optimization; Preclinical Development; Clinical Development; Parallel or concurrent development of multiple interventions; and Activities to support licensure and WHO prequalification. Applicants must include at least one Japanese organization and one non-Japanese organization. https://www.ghitfund.org/applyforfunding/pdp/en	Up to 5,000,000 JPY, for up to 2 years Cost sharing required	Letter of intent: 11/18/26 Proposal: 12/16/16

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		IMMUNOLOGY & INFECTIOUS DISEASE		
37.	Target Research Platform (GHIT Fund)	The Target Research Platform (TRP) is intended to support the crucial, earlier phase of R&D discovery of new approaches, concepts, constructs and solutions to fight neglected infectious diseases. Three awards are included: Standard TRP Award; Strategic Innovation and Market Assessment Award (SIMA Award); and Pandemic Preparedness and Response Award (PPR Award). https://www.ghitfund.org/applyforfunding/trp/en	Up to 100,000,000 JPY, for up to 2 years Dependent upon award mechanism	Letter of intent: 11/18/26 Proposal: 12/16/16
		MEDICAL COUNTERMEASURES (1)		
38.	Draft RPP for Medical Countermeasure Clinical Research Centers (MCCRC) Centralized Digital Infrastructure (BARDA/RRPV)	This solicitation intends to establish a centralized, secure, scalable, and regulatory-compliant digital infrastructure for the long-term management of clinical research data and electronic Trial Master Files (eTMFs) from completed BARDA studies. The capability will support the secure preservation, management, controlled access, and rapid retrieval of clinical, nonclinical, laboratory, regulatory, and related study data and documentation. This effort will enhance data integrity, regulatory and inspection readiness, cybersecurity, continuity of operations and reuse of BARDA-funded research assets to support future medical countermeasure development and public health preparedness and response. https://www.rrpv.org/opportunities/	TBD	TBD
		MEDICAL MANUFACTURING (1)		
39.	Future Solicitation: Repurposing Equipment for Drug Delivery (REDD) (BioMaP)	REDD intends to seek offerors who can assume ownership of available government equipment and leverage those assets to manufacture an emergency autoinjector platform, featuring a novel glass-free, collapsible, primary drug container (PDC) with the final intent to develop a new drug delivery device or platform. https://www.biomap-consortium.org/solicitation/future_solicitation_redd/	TBD	TBD
		MUSCULOSKELETAL HEALTH (1)		
40.	Automated Ultrasound-Based, Super Intelligence (SI)-Enabled Fracture Detection (BARDA) BARDA-FY27-10192026	BARDA seeks information on technologies that could assist clinical care providers in visualizing or detecting musculoskeletal injuries, including fractures and soft tissue injuries, to support triage and initial treatment in emergency departments, urgent care centers, and field settings. These devices could also support continued evaluation and treatment in definitive orthopedic care settings, consistent with applicable regulatory authorizations and intended uses. https://sam.gov/workspace/contract/opp/60c3f2ff8776454ebfd2be964ff59b68/view	RFI	Response: 11/18/26

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PARKINSON'S DISEASE (2)		
41.	Parkinson's Disease Biomarker Innovation and Advancement Program (MJFF)	The Parkinson's Disease Biomarker Innovation and Advancement Program accelerates the development of robust and reproducible measurement tools with defined contexts of use in Parkinson's disease. Through a continuous submission pathway, the program supports teams advancing biomarker technologies aligned with MJFF priorities. https://www.michaeljfox.org/grant/parkinsons-disease-biomarker-innovation-and-advancement-program	Dependent upon proposal, for up to 2 years	Proposal: 2/18/27
42.	Parkinson's Disease Therapeutics Pipeline Program (MJFF)	The Parkinson's Disease Therapeutics Pipeline Program advances therapeutic development through pre-clinical and/or into clinical testing of approaches addressing unmet needs of people with PD with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms. As the requirements for delivering new treatments into the market depend on specialized expertise and resources, a unique goal of this program is to promote clearer paths to commercialization and market access by the PD community. https://www.michaeljfox.org/grant/parkinsons-disease-therapeutics-pipeline-program	Up to $5 million, for up to 3 years Dependent upon award mechanism	Proposal: 1/14/27
		PATIENT-CENTERED RESEARCH (1)		
43.	Harnessing Digital Health Technologies To Support Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 1 2027 (PCORI)	This PFA will solicit applications proposing to address patient-centered CER questions that will fill DHT-related evidence gaps. DHTs include tools and devices using computing platforms, connectivity, software and/or sensors to support the individual needs and values of patients. PCORI is particularly interested in submissions that address the following Special Areas of Emphasis (SAEs): Enhance Self-Management of Health; Incorporate Patient-Generated Data Into Clinical Workflows; and Promote Individualized Health Management. https://www.pcori.org/funding-opportunities/announcement/harnessing-digital-health-technologies-support-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2027	Up to $12 million, for up to 5 years	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27
		PEDIATRIC HEALTH (3)		
44.	Forecast: Learning Disabilities Research Centers (NIH/NICHD) RFA-HD-28-006	This NOFO will support transdisciplinary research centers to improve outcomes for children and youth at risk for, or diagnosed with, specific learning disabilities (SLDs) impacting mathematics, reading and writing. These centers will focus on improving the identification and classification of SLDs, deepen understanding of their genetic and neurobiological underpinnings, and advance testing of innovative screening and intervention approaches. https://www.grants.gov/search-results-detail/364123	TBD	Estimated post date: 7/24/27 Estimated due date: 10/1/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PEDIATRIC HEALTH		
45.	Gabriella Miller Kids First Pediatric Research Program: Genomic Data Generation Center and Training and Outreach Core (U24 Clinical Trial Not Allowed) (NIH Common Fund) RFA-RM-27-008 RFA-RM-27-010	Genomic Data Generation Center(s) support rapid generation of high quality sequence and variant data from a large number of human specimens representing pediatric conditions, including childhood cancers and congenital anomalies. The Kids First TOC will collaborate with the Kids First Data Resource Center (DRC), which is charged with facilitating data collection, harmonization, and sharing and serves as a point of contact for existing Kids First Data. The TOC, in turn, will facilitate training, outreach, community engagement, and education for the Kids First Program and bolster efforts to enhance utilization of and participation in Kids First data resources. https://www.grants.gov/search-results-detail/358954 https://www.grants.gov/search-results-detail/358960	Up to $3.5 million per year, for up to 3 years (Data) Up to $900,000 per year, for up to 3 years (Outreach)	Proposal: 1/8/27
		REGULATORY SCIENCE (1)		
46.	FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science (FDA) FDABAA-27-00123	The FDA solicits advanced research and development proposals to support regulatory science and innovation. The FDA anticipates that research and development activities awarded under this BAA will serve to advance scientific knowledge to accomplish its mission to protect and promote the health of our nation. The 22 areas of interest include: Medical Countermeasures; Digital Health; Neurological Disorders; Oncology; Pediatric Health; Rare Diseases; Regenerative Medicine; and Women's Health. https://sam.gov/workspace/contract/opp/85dacc8ad6aa4cd59ae08f37a9f63355/view	Dependent upon proposal and award mechanism	Proposal: 1/22/27
		REPRODUCTIVE HEALTH (1)		
47.	Forecast: Discovery Gateway to Reproductive Health Innovation (NIH/NICHD) RFA-HD-28-001	NICHD seeks to establish a single Discovery Gateway to Reproductive Health Innovation, a comprehensive knowledgebase designed to advance research on male and female indications such as preeclampsia, endometriosis, preterm birth, infertility, and uterine fibroids. This initiative will expand shared resources and essential infrastructure for the biomedical research community. https://www.grants.gov/search-results-detail/364126	TBD	Estimated post date: 7/24/27 Estimated due date: 10/1/27
		SMALL BUSINESS DEVELOPMENT (2)		
48.	DoW SBIR/STTR 2027 BAA Release 2 (DoD) DoD SBIR 2027 BAA	Topics include: Validation and Verification of Computational Modeling of Human Blast Injury on Battlefield and Biolab Mirror: Artificial Intelligence / Machine Learning (AI/ML) Digital Twin for Intent Characterization and Bio-Containment Integrity. https://www.dodsbirsttr.mil/topics-app/	Up to $250,000, for up to 7 months (Phase I) Up to $1.5 million, for up to 2 years (D2P2)	Proposal: 1/6/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		SMALL BUSINESS DEVELOPMENT		
49.	Groundwork: An Emerging Innovator Accelerator (BARDA/MATTER)	Through expert-led workshops, mentorship, peer learning and practical application, participating founders will deepen their understanding of how healthcare works — from industry incentives and buying dynamics to compliance, go-to-market strategy and building a company. https://matter.health/challenges/groundwork-an-emerging-innovator-accelerator/	11-week accelerator program	Application: 11/22/26
		THERAPEUTICS (1)		
50.	Platforms to Identify Candidate Drugs – PICD (BARDA/VITAL)	Drug repurposing offers a compelling path forward by leveraging the established safety and pharmacology of existing medicines. Combined with recent advances in Super Intelligence (SI) and the growing availability of real-world data (RWD)—including electronic health records, insurance claims, and other clinical datasets—we have an unprecedented opportunity to transform how promising drug candidates are identified and prioritized. https://vitalhubhealth.com/picd/	TBD	TBD
		UROLOGY (1)		
51.	George M. O'Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional) (NIH/NIDDK) RFA-DK-28-314	The Urology Cooperative Research Centers foster impactful, multi-disciplinary research through collaborations within and outside the Centers and serve as a national resource for the urology research community. https://www.grants.gov/search-results-detail/360551	Up to $750,000 per year, for up to 5 years	Proposal: 2/1/27
		WOMEN'S HEALTH (5)		
52.	Women's Initiative for Screening and Health (WISH) (HHS/HRSA) HRSA-27-072	The purpose of WISH is to improve women's health across the lifespan by increasing access to and availability of preventive health services. Through a multidisciplinary coalition of healthcare providers, academic institutions, and patient-centered organizations, WISH drives a comprehensive strategy to: (1) review and recommend evidence-based updates to the HRSA-supported women's preventive service guidelines (Guidelines), (2) raise awareness and knowledge of the (Guidelines), and (3) increase adoption and use of the Guidelines in clinical practice. https://www.grants.gov/search-results-detail/363546	Up to $1 million	Proposal: 1/8/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		WOMEN'S HEALTH		
53.	AMPt: Autoimmune in Menopause and Pregnancy Transitions (Wellcome/Pivotal)	AMPt aims to build immune–endocrine models capable of predicting a woman's risk of autoimmune onset or flare with enough accuracy to design and deliver effective treatment. The goal is to return the equivalent of 1 healthy day a week to millions of women living with RA, MS, or lupus — as many as 52 healthy days a year, and up to 5 years across a lifetime. Achieving the goal requires predicting flares at least 4 weeks ahead and new disease at least 12 weeks ahead, catching seronegative RA inside its ~12-week treatment window, and together cutting the rate of flares and new disease by at least a third. https://wellcomeleap.org/programs/ampt/	Total funding of $50 million Projects should be 3 years	Abstract: 12/2/26 Proposal: 1/21/27
54.	COMpetency in Menopause & Integrated Therapy (COMMIT) Challenge (NIH/OWRH)	The goal of this Challenge is to identify and amplify curricula that comprehensively address the menopausal transition, including menopause hormone therapy, within U.S. health education programs. Eligibility is limited to degree-offering institutions. https://www.nih.gov/challenges/competency-menopause-integrated-therapy-commit-challenge	Total prizes of $2.5 million	Proposal: 1/26/27
55.	Forecast: MIDLIFE Health: Advancing Innovation in Women's Health (NIH/RADx/CIMIT)	MIDLIFE Health aims to help address this gap by supporting scalable, marketable, rigorously validated solutions that respond to women's unique needs, empower women in midlife, improve health outcomes, and set new benchmarks for quality and responsiveness. https://cimit.org/midlife/	Total prizes of $3.225 million	TBD
56.	Redefining Women's Health Translational Grant: From Heart to Head to Hormones (AHA)	Despite significant progress in biomedical and bioscience research, many conditions that disproportionately, differently, or distinctly impact women remain underdiagnosed, undertreated, and underfunded. This call focuses on three priority areas where transformative science and innovation are urgently needed: Cardio-Oncology ; Atrial Fibrillation in Women; and Circadian Science. https://professional.heart.org/en/research-programs/aha-funding-opportunities/redefining-womens-health-translational-grant	$100,000 for 1 year	Pre-proposal: 1/6/27 Full Proposal: 4/14/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ADVANCED RESEARCH PROJECTS AGENCY FOR HEALTH (4)		
57.	Resilient Systems Office (RSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-103	RSO is interested in innovations that take a systems level approach in areas including, but not limited to, systems biology, data systems, biophysical systems, health IT systems, sociotechnical systems, health-related systems engineering, and other systems with the potential to improve health outcomes. https://sam.gov/workspace/contract/opp/36eb58892e1f49f897c81d87ff7a95fe/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
58.	Health Science Futures (HSF) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-104	HSF awardees will develop innovative technologies, tools, and platforms that can be applied to a broad range of diseases. The following interest areas define the ground-breaking research we seek to support: Breakthrough Technologies; Transformative Tools; and Platform Systems. https://sam.gov/workspace/contract/opp/29c3ac2ea6754d1f897f9c71204c0eea/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
59.	Scalable Solutions Office (SSO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-105	ARPA-H SSO seeks solutions to improve the scalability and affordability of health care solutions, bridge gaps in underserved areas, and extend remote access to expertise by developing location-specific interventions, telemedicine solutions, and mobile health clinics. Solutions should focus on rapid innovation and the use of partnerships, also flexible distribution networks and streamlined manufacturing processes. SSO interest areas include: Advanced Technologies for Medical Product and Capability Distribution; and Biomanufacturing Innovations. https://sam.gov/workspace/contract/opp/c79df057a7e44d2cb3072e4ce3307422/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29
60.	Proactive Health Office (PHO) Mission Office Innovative Solutions Opening (ISO) ARPA-H-SOL-24-106	The Proactive Health Office (PHO) at ARPA-H is seeking solutions to improve the healthspan and health outcomes of Americans prior to the onset of disease and/or the development of diminished quality of life from illness. Interest areas include: Novel prevention, detection and prophylactic treatment methods for disease; Population-level approaches to increase the adoption of prevention and wellness behaviors; and System innovation for the delivery of proactive health outcomes. https://sam.gov/workspace/contract/opp/a5b72db5139040f8b2a1dcc2d2c96733/view	Dependent upon proposal and award mechanism	Proposal: 3/5/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		AIR FORCE (4)		
61.	Continuing Human Enabling, Enhancing, Restoring and Sustaining (CHEERS) FA238424S2233	CHEERS MAA is intended to provide a comprehensive strategy for AFRL/RH and USAFSAM's range of S&T, allowing for progression from basic research to technology maturation and transition. Areas of interest include: Aerospace Medicine and Physiology; Public Health and Preventative Medicine; Occupational Medicine and Bioenvironmental Engineering; and En Route Care/Expeditionary Medicine/Prolonged Field Care. https://sam.gov/opp/06fcf51457dc4361856ae1f691c70194/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis
62.	AFRL/RX Functional Materials Open BAA FA8650-22-S-5002	The Functional Material Open BAA seeks to exploit innovative functional materials that enable new warfighting capabilities, significantly improve the effectiveness of warfighters and their current and future systems and solve urgent operational needs. The Biomaterials Materials and Processes (BM&P) Research area seeks to accelerate materials development, protect assets from the environment, and enable airman performance. This research area harnesses materials and processes competencies in soft matter materials characterization, molecular and synthetic biology, microbiology, biochemistry, bioinformatics, machine learning, multiscale modeling, bioelectronics, bio- functionalization, and biological engineering to create materials not easily achievable through traditional chemical synthesis or additive manufacturing. https://sam.gov/opp/2fadb41c2700409c993a8c308c6f5120/view	Dependent upon proposal and award mechanism	White paper: 10/28/28
63.	Research Interests of the Air Force Office of Scientific Research FA9550-26-S-0001	The focus of AFOSR is on research areas that offer significant and comprehensive benefits to our national war fighting and peacekeeping capabilities. The Chemistry and Biological Sciences Team is responsible for research activities in chemistry and biological sciences. The focus is on complex materials, microsystems and structures and well as systems of a biological natural by incorporating hierarchical design of mechanical and functional properties from the nanoscale through the mesoscale, ultimately leading to controlled well- understood chemistry/biochemistry, and material or structural behavior capable of dynamic functionality and/or performance characteristics to enhance mission versatility. https://grants.gov/search-results-detail/362681	Dependent upon proposal, for up to 5 years	White papers accepted on a rolling basis
64.	Research Interests of the United States Air Force Academy USAFA-BAA-2021	USAFA invites white papers and proposals for research in many broad areas, under the direction of several research centers. One such center, is the Life Sciences Research Center (LSRC). LSRC intrigued by biomaterials found in nature, which use unique biologic design principles and processes to form novel structures. The USAF requires lighter, tougher materials, which can hold up under extreme temperature, pressure or loading conditions. https://www.grants.gov/search-results-detail/330175	Dependent upon proposal, for up to 5 years	Proposals accepted on a rolling basis

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY (10)		
65.	The Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense Broad Other Transaction Authority Announcement (BOTAA) BOTAA-24-01	JPEO-CBRND is interested in efforts directed toward the development of enabling technologies that speed up the advanced development process. Areas of interest include: Software and Artificial Intelligence (AI), wearable sensors, threat detection, biothreat containment and aeromedical evaluation. https://sam.gov/opp/2d04622b25364669857a6a61c576ade9/view	Dependent upon proposal	Preproposals accepted through 2/7/29
66.	BAA R&D in Support of the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND), JPM Medical and JPL EB CBRND-BAA-22-01	The JPMO is interested in studies on new and better ways to develop medical CBRN countermeasures more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking. Mission areas include: Biological Medical Prophylaxis; Medical, Chemical, and Biological Countermeasures; Medical Radiological Countermeasures; Medical Diagnostic and Surveillance Systems; and Enabling Biotechnologies and Response Systems. https://sam.gov/opp/e7c3faad3433434aaf41a5eb5ce11920/view	Dependent upon proposal	Proposals accepted on a rolling basis through 12/31/2060
67.	USAMRDC Broad Agency Announcement for Extramural Medical Research HT9425-23-S-BAA1	R&D funded by this BAA are expected to benefit and inform both military and civilian medical practice and knowledge. Research areas include: Military Infectious Disease; Combat Casualty Care; and Military Operational Medicine. https://www.grants.gov/search-results-detail/343725	Dependent upon proposal, for up to 5 years	Pre-applications accepted until 9/30/27 Full proposal by invitation
68.	USSOCOM BAA for Extramural Biomedical and Human Performance Research and Development HT9425-23-S-SOC1	A primary emphasis of the USSOCOM Biomedical, Human Performance, and Canine Research Program is to identify and develop techniques, knowledge products, and materiel for early intervention in life-threatening injuries; prolonged field care (PFC); human performance optimization; canine medicine/performance; brain health; immune response; automation of systematic reviews and metanalysis; and novel post-traumatic stress, depression, and anxiety treatment. Special Operations Forces (SOF) medical personnel place a premium on medical equipment that is small, lightweight, ruggedized, modular, multi-use, and designed for operation in extreme environments. https://www.grants.gov/search-results-detail/349586	Dependent upon proposal	Proposals accepted through 7/31/28 Submission of a pre-proposal is required
69.	Medical CDID BAA MED CDID	MED CDID invites innovative proposals that allow future Army medical units to efficiently and effectively clear the battlefield (evacuation of wounded, ill, and injured), maximize return to duty, and overcome contested logistics. https://vulcan-sof.com/login/ng2/submission?collectionUuid=5417cc3c-2b60-446a-addf-c0bea38cd0b1	Dependent upon proposal	White papers accepted through 12/31/2030

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		ARMY		
70.	Army Research Office Laboratory Broad Agency Announcement for Foundational Research W911NF-23-S-0001	ARL's foundational research mission spans basic research and applied research but may include advanced technology development and advanced component development and prototypes when opportunities arise to directly or indirectly help achieve ARL's mission. Topics include Biotronics, Genetics, and Neurophysiology of Cognition; the full list of research topics is available here: https://www.arl.army.mil/opportunities/arl-baa/ https://sam.gov/opp/7560e5d4024b4e94ad3eab6180cfcc36/view	Dependent upon proposal	Proposals accepted on a rolling basis until 11/20/27
71.	Army Research Institute for the Behavioral and Social Sciences Broad Agency Announcement for Basic, Applied, and Advanced Research W911NF-23-S-0010	ARI seeks Applied Research proposals that provide a systematic expansion and application of knowledge to design and develop useful strategies, techniques, methods, tests, or measures that provide the means to meet a recognized and specific Army need. Applied Research precedes specific technology investigations or development and should have high potential to transition into advanced technology. https://sam.gov/opp/ee8d9eeec4f94269b6e1ac16b09d9417/view	Dependent upon proposal	Proposals accepted on a rolling basis until 4/30/28 Full proposal required
72.	Army Applications Lab BAA for Disruptive Applications W911NF-24-S-0008	AAL is seeking technologies that address a wide range of Army needs consistent with CFT capability focus areas and associated programs and lines of effort as well as potentially disruptive new capabilities that augment or enhance Army capability overmatch. https://sam.gov/opp/3f8ec6d36d584ca28364a2f8a10255b7/view	Dependent upon proposal	Proposals accepted through 4/4/29 Pre-proposal is required
73.	Basic and Applied Research at the US Army Combat Capabilities Development Command - Soldier Center W911QY-25-R-0023	The Soldier Center is seeking solutions in the following scientific and technical areas: Combat Feeding & Equipment; Soldier Protection & Survivability; Modeling & Simulation; Human Performance & Biomechanics; Expeditionary Maneuver Support; Aerial Delivery; and Simulation & Training Technology. https://sam.gov/opp/e85e373d22ef47018b0336fc6a258002/view	Dependent upon proposal	Concept papers accepted on a rolling basis until 2/27/30
74.	BAA for Chemical, Biological, Radiological, Nuclear, and Explosive Defense Efforts W911SR-24-R-DEVB	DEVCOM CBC's mission is to provide innovative chemical, biological, radiological, nuclear and explosive (CBRNE) defense capabilities to enable the Joint Warfighters' dominance on the battlefield and interagency defense of the homeland. Mission areas include: Sensor technologies and biomaterials; Biological point detection; Chemical point detection; Early warning and detection; Collective protection; Respiratory protection; Decontamination; CBRN countermeasures; and Chemical biological advanced materials and manufacturing science. https://sam.gov/opp/85b4747beec740979ac430ee987bda8c/view	Dependent upon proposal and award mechanism	Preproposals accepted through 8/20/29

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		BARDA (2)		
75.	BARDA Broad Agency Announcement BAA-23-100-SOL-00004	BARDA is accepting proposals related to diagnostics and POC tests for COVID and other MCM topics that include: CBRN Vaccines, Antivirals & Antitoxins; Antimicrobials; Radiological/Nuclear MCMs; Chemical Threat MCMs; Burn and Blast Medical MCMs; Diagnostics; Influenza & Emerging Diseases vaccines and therapeutics; ImmuneChip+; Flexible and Strategic Therapeutics (FASTx). https://sam.gov/workspace/contract/opp/8170c4735df64714adb2d1f8ce8671b1/view	Dependent upon proposal	Proposal: 9/25/28
76.	BARDA DRIVe EZ-BAA DRIVeEZBAA22100SOL00003	All AOIs are currently closed. No initial awards will be executed. Eligible +Phase submissions will still be accepted and reviewed in accordance the process outlined the EZBAA and corresponding AOI. https://sam.gov/opp/6684d4a2734047d58d6cbf7e50bdd00a/view	Up to $750,000 per award	Proposals accepted on a rolling basis Deadlines vary by AOI
		DARPA (3)		
77.	Expedited Research Innovation System (ERIS) DARPA-PS-25-05	DARPA seeks to obtain solutions or capabilities that deliver breakthrough technological advancements that are new as of the date of submission; or technologies, processes, research or methods. Topics include: Advanced technologies for defense against potential chemical and biological threats, human-made or naturally occurring; Advanced technologies for the improved resilience of US operations throughout the prepare, deployment, execute, and return cycle; and Development of groundbreaking methods and metrology for complex, emergent, and adaptive systems, going beyond the limitations of current reductive scientific methods. https://sam.gov/opp/41adb60c65954ac5be65b6d064ae9c74/view	Dependent upon proposal and award mechanism	Proposal: 7/31/27
78.	Biological Technologies BAA HR001124S0034	Research in BTO creates biotechnological capabilities that provide tactical care and restore function to injured warfighters, increase operational resilience, develop novel functional materials, and detect and protect against threats to maintain force readiness. BTO is interested in submissions related to the following topic areas: AI/ML; Combat Casualty Care; Human Performance; Materials, Sensors, Processing; Agricultural and Environmental; Security, Safety, and Surveillance; and Biomedical and Biodefense. https://sam.gov/workspace/contract/opp/8d403582edfd409795560247e8d229b7/view	Dependent upon proposal	Abstracts & proposals accepted on a rolling basis
79.	Defense Sciences Office, Office-wide HR001126S0015	The DSO Office-wide BAA invites proposers to submit innovative basic or applied research concepts or studies and analysis proposals that address one or more of the following technical thrust areas: Materials, Manufacturing, & Structures; Sensing and Measurement; Math, Computation, and Processing; Complex, Dynamic, and Intelligent Systems. https://sam.gov/opp/b77f1caefb244d1193ded7f6187ede52/view	Dependent upon proposal	Abstracts accepted on a rolling basis until 8/27/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		DEFENSE THREAT REDUCTION AGENCY (4)		
80.	Research and Development Innovations Broad Agency Announcement HDTRA1-22-S-0003	DTRA seeks proposals that will advance research, development, test, and evaluation priorities across five interrelated thrust areas derived from the 2022 DTRA Strategic Plan for RDT&E: Understand current and emerging WMD situations, threats, and capabilities; Enable effective and integrated WMD deterrence; Control, disable, and defeat current and emerging WMD threats; Protect the force and mitigate crises from WMD; Enable cross-cutting capabilities. https://sam.gov/workspace/contract/opp/d5bcd60592c84adf908c5c1ca747bc4e/view	Dependent upon proposal, for up to 18 months	White papers accepted on a rolling basis through 2/14/27
81.	Biological Threat Reduction with Global Partners Broad Agency Announcement (BAA) HDTRA1-24-S-0002	BTRP supports international health security efforts to address diseases caused by U.S. Biological Select Agents, pathogens of pandemic potential, and emerging infectious diseases. BTRP achieves its mission through collaboration with partner countries and the international community to minimize the threat of deliberate, accidental, and natural infectious disease outbreaks through enhanced detection, diagnosis, and reporting capabilities and biosecurity and biosafety measures. https://www.grants.gov/search-results-detail/353860	Dependent upon proposal and award mechanism	Proposal: 4/28/29
82.	FY25-29 Strategic Trends Research Initiative Broad Agency Announcement HDTRA1-24-S-0003	SI-ST's research explores a range of challenges related to nuclear, chemical, and biological weapons. The three WMD-relevant Research Thrust Areas are: strategic international dialogues, analytical studies, and emerging CWMD researcher projects. An area of general interest is: Future trends related to biological warfare, biodefense, biosecurity, and bio preparedness. https://sam.gov/opp/7a98bf70ac2a49c8b8e0d71abbc93750/view	Dependent upon proposal and award mechanism`	White papers accepted on a rolling basis through 8/1/29
83.	Fundamental Research to Counter Weapons of Mass Destruction (C-WMD) HDTRA1-25-S-0001	Fundamental research efforts enable capabilities such as development of improved detection devices; development of diagnostics; increasing knowledge and improved capabilities for development of new or improved medical and material countermeasures to CB threats for both pre- and post-exposure scenarios; enhanced personal protection against, modeling of, prevention of, or decontamination of CB threats; and providing effective elimination strategies via non-kinetic approaches for threat agent destruction, neutralization and/or sequestration. https://www.grants.gov/search-results-detail/356612	Up to $1 million per year, for up to 5 years	White papers accepted through 9/2034
		DEPARTMENT OF ENERGY (1)		
84.	FY 2027 Continuation of Solicitation for the Office of Science Financial Assistance Program DE-FOA-0003665	SC accomplishes its mission and advances national goals by supporting: The frontiers of science—exploring nature's mysteries from the study of fundamental subatomic particles, atoms, and molecules that are the building blocks of the materials of our universe and everything in it to the DNA, proteins, and cells that are the building blocks of life. https://www.grants.gov/search-results-detail/363993	Dependent upon award mechanism	Proposals accepted on a rolling basis through 9/30/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NATIONAL SCIENCE FOUNDATION (3)		
85.	Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs SBIR/STTR: Developing Deep Technologies that Advance U.S. Competitiveness and Security NSF 26-510	The NSF SBIR/STTR programs invest in start-ups and small businesses to turn high-risk, high-impact research into market-ready innovations. These programs aim to advance innovation by investing in the development of critical and emerging technologies that yield market-ready or commercializable outputs, all the while harnessing the full geography of American innovation and building a competition-ready workforce. https://www.nsf.gov/funding/opportunities/small-business-innovation-research-small-business-technology/nsf26-510/solicitation	Up to $305,000, for up to 18 months (Phase I) Only NSF Phase I SBIR/STTR awardees are permitted to submit a Phase II proposal	Project pitches accepted on a rolling basis; full proposal due 3/4/27
86.	Small Business Innovation Research / Small Business Technology Transfer Phase I, Phase II, Fast-Track Programs : A Pilot Emphasis on Scientific Instrumentation NSF 26-511	The NSF SBIR/STTR and Fast-Track programs assist startups and small businesses in developing next-generation scientific instrumentation to support the S&E enterprise. These programs aim to spur innovation by investing in the development of critical and emerging technologies that advance basic science, innovation, and commercialization, thereby making entirely new fields of scientific discovery possible. https://www.nsf.gov/funding/opportunities/small-business-innovation-research-small-business-technology-0/nsf26-511/solicitation	Up to $305,000, for up to 18 months (Phase I) Only NSF Phase I SBIR/STTR awardees are permitted to submit a Phase II proposal	Project pitches accepted on a rolling basis; full proposal due 3/4/27
87.	Engineering (ENG): Chemical, Bioengineering, Energy, and Transport Systems (CBET) NSF 26-518	NSF ENG supports foundational engineering research for chemical, bioengineering, energy, and transport systems through the following programs: EBBS supports foundational engineering research on platforms, devices, organisms, tissues, and processes that advance knowledge and control of biological functions. TP supports foundational engineering research to understand, model, and control the transport of mass, momentum, energy, and species across multiple scales. CPS supports foundational engineering research in chemical and biochemical processes for chemicals, fuels, energy, and materials. EWRE supports foundational engineering research to manage energy, water, minerals, and material resources. https://www.nsf.gov/funding/opportunities/engineering-eng-chemical-bioengineering-energy-transport/nsf26-518/solicitation	Dependent upon proposal, for up to 5 years	Proposals accepted anytime

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		NAVY (2)		
88.	FY25 Long Range Broad Agency Announcement for Navy and Marine Corps Science and Technology N0001425SB001	The ONR, ONR Global, and Marine Corps Warfighting Lab are interested in receiving proposals for Long-Range S&T Projects which offer potential for advancement and improvement of Navy and Marine Corps operations. https://sam.gov/workspace/contract/opp/0efe2fde0926428f8ecc073f3fc7b5d9/view	Dependent upon proposal	Proposals accepted on a rolling basis until 12/31/26
89.	NRL Long Range Broad Agency Announcement (BAA) for Basic and Applied Research N00173-24-S-BA01	The Naval Research Laboratory is seeking to advance technology developed for in vitro diagnostic devices that are amenable to military hardening and integration with communication capabilities to support the medical diagnostic and epidemiological detection and biosurveillance needs of the US military across multiple Echelons of Care and specifically for field deployment at Echelons 1 or 2. https://sam.gov/workspace/contract/opp/0c6f40ff4b65423c821921aa8b94a62e/view	Dependent upon proposal and award mechanism	White papers accepted through 12/30/26
		OFFICE OF THE UNDERSECRETARY OF DEFENSE (1)		
90.	OUSD (R&E) Seeks Advanced Manufacturing, Prototypes and Materials (AMPAM) HQ003425BOTA1	OUSD (R&E)'s goal is to foster increased collaboration and partnership between Government and Industry to identify, develop, and mature new or improved manufacturing and repair processes and bridge the gap between discovery and implementation of new capabilities for the warfighter. Examples may include Bio-manufacturing of medical related material and Bio-manufacturing of materials or products in the supply chain. https://sam.gov/opp/64a31b87112843b58dfb13f37bfa3df1/view	Dependent upon proposal and award mechanism	White papers accepted on a rolling basis through 10/2/27
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE (4)		
91.	Broad Pragmatic Studies Funding Announcement -- Cycle 1 2027	PCORI is interested in research that fills pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader healthcare community make informed decisions about their health care and health outcomes. Applicants for the 2027 BPS PFA may select up to three of PCORI's Topic Themes; or ""Other."" Cycle 1 SAEs include: Optimizing Treatment and Symptom Management to Reduce Toxicities and Improve Patient-Centered Outcomes in Cancer Patients; Serious Mental Illness Prevention, Care and Treatment; Improving Mental Health and Substance Use Outcomes for Pregnant and Postpartum Populations; and Enhancing support services to improve mental health and address stigma experienced by individuals with sensory health conditions, their families and care partners. https://www.pcori.org/funding-opportunities/announcement/broad-pragmatic-studies-pcori-funding-announcement-cycle-1-2027	Up to $12 million, for up to 5 years Dependent upon award mechanism	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27

	Title (Agency) and Opportunity #	Description and Link	Funding Level	Deadline
		PATIENT-CENTERED OUTCOMES RESEARCH INSTITUTE		
92.	Phased Large Awards for Comparative Effectiveness Research -- Cycle 1 2027	PCORI is interested in research that aims to fill pertinent evidence gaps representing decisional dilemmas for patients, caregivers, clinicians, policymakers and other healthcare system stakeholders, with a goal of generating evidence that helps patients and members of the broader health and healthcare community make informed decisions about their health care and health outcomes. Applicants must address PCORI's Foundational Expectations for Partnerships in Research when applying for PCORI research funding, developing project and engagement plans for awarded projects and reflecting on engagement during a project to improve and strengthen engagement over time. https://www.pcori.org/funding-opportunities/announcement/phased-large-awards-comparative-effectiveness-research-pcori-funding-announcement-cycle-1-2027	Up to $22 million, for up to 6.5 years	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27
93.	Improving Methods for Conducting Patient-Centered Comparative Clinical Effectiveness Research PCORI Funding Announcement -- Cycle 1 2027	PCORI seeks to fund projects that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by CER studies. For the Cycle 1 2027 Methods PFA, PCORI has identified the following programmatic priority areas that address important methodological gaps and lead to improvements in the strength and quality of evidence generated by patient-centered CER studies: Methods To Support the Use of Patient-Centered Measurement in Patient-Centered CER; Methods To Support the Use of Real-World Data (RWD) in Multi-Site Patient-Centered CER; Methods To Improve the Use of AI/ML in Patient-Centered CER; and Methods To Improve Study Design in Patient-Centered CER. https://www.pcori.org/funding-opportunities/announcement/improving-methods-conducting-patient-centered-comparative-clinical-effectiveness-research-pcori-funding-announcement-cycle-1-2027	Up to $750,000, for up to 3 years	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27
94.	Advancing the Science of Engagement in Research PCORI Funding Announcement -- Cycle 1 2027	This PFA will fund studies that build an evidence base on engagement in research, including: Measures to capture structure/context, process, and outcomes of engagement in research; Techniques that lead to effective engagement in research; and How effective engagement techniques should be modified and resourced for different contexts, settings, and communities. It will solicit applications that focus on: Development and validation of measures to capture structure/context, process and outcomes of engagement, for both stakeholders and investigators; and Development and/or testing of engagement methods to generate evidence on the most effective approaches for engagement. https://www.pcori.org/funding-opportunities/announcement/advancing-science-engagement-research-pcori-funding-announcement-cycle-1-2027	Up to $1.5 million, for up to 3 years	System opens: 11/17/26 Letter of intent: 1/6/27 Proposal: 5/4/27

GBG Acronyms

Updated Monthly
November 10, 2026
https://www.g2gconsulting.com/gbg-reporting-service/

Terms
AoI: Area of Interest
BAA: Broad Agency Announcement
FOA: Funding Opportunity Announcement
IC: NIH Institutes and Centers
NOFO: Notice of Funding Opportunity
NOSI: Notice of Special Interest
PI: Principal Investigator
RFI: Request for Information
RFP: Request for Proposal
SBIR: Small Business Innovation Research
SDOH: Social Determinants of Health
STTR: Small Business Technology Transfer
TRL: Technology Readiness Level

Agencies
ARPA-H: Advanced Research Projects Agency for Health
ASPR: Administration for Strategic Preparedness and Response
BARDA: Biomedical Advanced Research and Development Authority
CDC: Centers for Disease Control and Prevention
CDMRP: Congressionally Directed Medical Research Programs
DARPA: Defense Advanced Research Projects Agency
DHA: Defense Health Agency
DoD: Department of Defense
FDA: U.S. Food and Drug Administration
MTEC: Medical Technology Enterprise Consortium
NIH: National Institutes of Health
NSF: National Science Foundation
PCORI: Patient-Centered Outcomes Research Institute
USAMRDC: U.S. Army Medical Research and Development Command
USAMRIID: U.S. Army Medical Research Institute of Infectious Diseases
USSOCOM: United States Special Operations Command

NIH Institutes and Centers
CC: NIH Clinical Center
CIT: NIH Center for Information Technology
CSR: NIH Center for Scientific Review
FIC: Fogarty International Center
NCATS: National Center for Advancing Translational Sciences
NCCIH: National Center for Complementary and Integrative Health
NCI: National Cancer Institute
NEI: National Eye Institute
NHGRI: National Human Genome Research Institute
NHLBI: National Heart, Lung, and Blood Institute
NIA: National Institute on Aging
NIAAA: National Institute on Alcohol Abuse and Alcoholism
NIAID: National Institute of Allergy and Infectious Diseases
NIAMS: National Institute of Arthritis & Musculoskeletal & Skin Diseases
NIBIB: National Institute of Biomedical Imaging and Bioengineering
NICHD: Eunice Kennedy Shriver National Institute of Child Health and Human Development
NIDA: National Institute on Drug Abuse
NIDCD: National Institute on Deafness and Other Communication Disorders
NIDCR: National Institute of Dental and Craniofacial Research
NIDDK: National Institute of Diabetes and Digestive and Kidney Diseases
NIEHS: National Institute of Environmental Health Sciences
NIGMS: National Institute of General Medical Sciences
NIMH: National Institute of Mental Health
NIMHD: National Institute on Minority Health and Health Disparities
NINDS: National Institute of Neurological Disorders and Stroke
NINR: National Institute of Nursing Research
NLM: National Library of Medicine

Join the private GBG Zoom Meeting:
https://us06web.zoom.us/j/85360155978?pwd=LWv0LoQ8wPJQyPiLvThLSNGQoMdGoi.1
Meeting ID: 853 6015 5978 Passcode: 552411

Back to Table of Contents